Free Trial

Bicara Therapeutics (BCAX) Stock Price, News & Analysis

Bicara Therapeutics logo
$11.32 -0.52 (-4.39%)
Closing price 04:00 PM Eastern
Extended Trading
$11.32 0.00 (0.00%)
As of 06:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Bicara Therapeutics Stock (NASDAQ:BCAX)

Key Stats

Today's Range
$11.22
$11.84
50-Day Range
$8.71
$11.93
52-Week Range
$7.80
$28.09
Volume
139,871 shs
Average Volume
594,680 shs
Market Capitalization
$617.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.25
Consensus Rating
Buy

Company Overview

Receive BCAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCAX Stock News Headlines

HC Wainwright Cuts Bicara Therapeutics (NASDAQ:BCAX) Price Target to $40.00
He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.tc pixel
FY2025 EPS Estimates for BCAX Reduced by Cantor Fitzgerald
Q3 EPS Forecast for Bicara Therapeutics Lowered by Analyst
See More Headlines

BCAX Stock Analysis - Frequently Asked Questions

Bicara Therapeutics' stock was trading at $17.42 at the start of the year. Since then, BCAX shares have decreased by 35.0% and is now trading at $11.32.

Bicara Therapeutics Inc. (NASDAQ:BCAX) issued its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.04.

Bicara Therapeutics (BCAX) raised $315 million in an initial public offering on Friday, September 13th 2024. The company issued 17,500,000 shares at $18.00 per share.

Top institutional shareholders of Bicara Therapeutics include Vestal Point Capital LP (9.16%), Geode Capital Management LLC (1.23%), Bank of America Corp DE (0.83%) and Schroder Investment Management Group (0.78%).
View institutional ownership trends
.

Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/12/2025
Today
8/25/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BCAX
Previous Symbol
NASDAQ:BCAX
CIK
2023658
Fax
N/A
Employees
32
Year Founded
N/A

Price Target and Rating

High Price Target
$48.00
Low Price Target
$8.00
Potential Upside/Downside
+180.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.17)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$68 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-21.67%
Return on Assets
-20.89%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
25.80
Quick Ratio
25.80

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.04 per share
Price / Book
1.27

Miscellaneous

Outstanding Shares
54,560,000
Free Float
N/A
Market Cap
$627.99 million
Optionable
N/A
Beta
N/A

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:BCAX) was last updated on 8/25/2025 by MarketBeat.com Staff
From Our Partners